TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Complete Response (Percentage of Patients)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in K-ADHD Rating Scale Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Response Based on K-ARS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Remission Based on K-ARS Total Score and CGI-I Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilation affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: AUC for antibody drug conjugate (ADC), total antibody (TA), derivative 4 of maytansine (DM4), and S methyl derivate of DM4 (DM4-Me)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for ADC, TA, DM4 and DM4-Me
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Vascular Complications
Endpoint domain: Adverse events/effects
Primary endpoint: heart rate control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-Reported Buprenorphine Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically Verified Buprenorphine Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cases with histologic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricle volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary Cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with treatment-related adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-infusion lacosamide plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EKG, PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Education achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Amount of drop-out
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lower Respiratory Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abnormal Involuntary Movement Scale (AIMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Sensitivity and specificity of biosensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abdominal Muscle Endurance: Crunch test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extensors Muscle Endurance: Sorenson test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of trunk muscles: Peak Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose AUC lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival to days 28 and 60 post-randomization
Endpoint domain: Mortality/survival
Primary endpoint: Survival to Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change From Baseline in Plasma HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Plasma Glucose AUC 0 - 4 Hours Following OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Who Achieved Donor Cell Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fitness of patients prior to cancer surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reasons of death in patients with septic shock
Endpoint domain: Mortality/survival
Primary endpoint: Successful diagnosis of patient's condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate confirmed by histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of overall quality of life score as measured by Short Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis accuracy of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive tissue and blood biomarkers for response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaire scoring each step of performing the self-test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients who develop macular edema
Endpoint domain: Adverse events/effects
Primary endpoint: Mean IOP change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile Function (EF)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Seroma Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Average global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of intravenous injections
Endpoint domain: Adverse events/effects
Primary endpoint: Antiviral efficacy of infused CTLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological efficacy of infused CTLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in LV end systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV end diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum amplitude in thrombelastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Triple Therapy Initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall objective response rates after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Mean Pain Score at Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-for-age z-score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with digestive pathology and/or significant gastrointestinal lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful first vein cannulation attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of stuttering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physiological factors associated with stuttering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose limiting treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, severity and causal relationship of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in vital sign measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving a good or moderate DAS28 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of expansion of the aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of lidocaine and prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of lidocaine and prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained change in weight (for less) of 5% of previous body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: General Verbal Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CPC 3-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Levels (HOMA IR, QUICKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: snore time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: snore counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: snore sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partners diagnosed with HIV and HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Confidence in Assessing and Treating OUD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likeliness to Recommend Use of the OUD-CDS
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: CRC screening rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of grade 2 xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: 11-point Numeric Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Deep Venous Disease Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Population mean plasma level/time profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain following HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Urate Maximum Percentage Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine Uric Acid Percentage Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal Clearance of Uric Acid Percentage Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with curative effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Nerve Conduction Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Major Depression remission to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % adiposity (DEXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events related to Grazax
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response as assessed by fusion PET/CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of IMA-026
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of IMA-026
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Necrosis Factor-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oropharyngeal leak pressure volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of the sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best overall tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 60 day Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 120 day medication adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nausea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of Bleeding Events: HAS-BLED Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Thromboembolic Events: CHADS2 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Therapeutic Range (TTR) Values During the Last 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful remnant ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Cytokine Release AE
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Overall Maximum Cytokines Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global Response Assessment (GRA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Verbal Fluency FAS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants achieved complete remission of CMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection rate of clinically significant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: blood culture positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma polyphenol metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically relevant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically relevant changes in laboratory measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically relevant changes in electrocardiograms (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: liver fat contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fetuin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of biomarkers decreasing greater than 20% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin general appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin elasticity and visible cracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in CAPS-5 Total Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Contact Sexual Violence Via Physical Tactics
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Contact Sexual Violence Via Non-physical Tactics
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Non-contact Sexual Violence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Prosocial Bystander Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Nocturnal transcutaneous pressure CO2 (PtCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recorded Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pain score using functional pain scale questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score using FACES pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score using numeric 0-10 rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Agreement of ultrasound diagnosis with reference standard diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cocaine Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binding of fluorescent-labeled peptide to esophageal neoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of MEDI6469
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of fatal and non-fatal cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with solicited local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with solicited general adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of ED blood cultures contaminated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in bone mineral density of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ki-67 in Breast Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of intervention completion
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of patients with positive anti-COVID19 serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Binge Eating Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Smoking Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients spared surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ventilation Defect Percent (VDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Acute Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity at Day 100
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colour change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of major complications as vascular injury or ureteric injury
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic value for breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic value for suspicious breast lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Activity Score (DAS) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of Low Frequency Fluctuations (ALLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional Homogeneity (ReHo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corneal Endothelial Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes